share_log

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

諾瓦瓦克斯醫藥 | DFAN14A：其他委託徵集材料
美股sec公告 ·  05/14 04:15
牛牛AI助理已提取核心訊息
Shah Capital Management, Inc., along with its affiliates, has filed a preliminary proxy statement with the SEC to solicit votes against the election of three Novavax, Inc. board members at the upcoming annual meeting on June 13, 2024. The hedge fund, which owns approximately 7.5% of Novavax and is one of its top three shareholders, is also urging stockholders to vote against certain company proposals, including executive compensation amendments. Shah Capital's actions follow a recent licensing agreement between Novavax and Sanofi, which boosted Novavax's stock by over 100%. The fund has been critical of Novavax's current management and marketing strategies, believing the company to be undervalued. Shah Capital has nominated two new board members to aid in turning around the company's fortunes. The fund highlights Novavax's strong IP portfolio and the potential market for non-mRNA protein vaccines, as acknowledged by the CDC's report on vaccine effectiveness.
Shah Capital Management, Inc., along with its affiliates, has filed a preliminary proxy statement with the SEC to solicit votes against the election of three Novavax, Inc. board members at the upcoming annual meeting on June 13, 2024. The hedge fund, which owns approximately 7.5% of Novavax and is one of its top three shareholders, is also urging stockholders to vote against certain company proposals, including executive compensation amendments. Shah Capital's actions follow a recent licensing agreement between Novavax and Sanofi, which boosted Novavax's stock by over 100%. The fund has been critical of Novavax's current management and marketing strategies, believing the company to be undervalued. Shah Capital has nominated two new board members to aid in turning around the company's fortunes. The fund highlights Novavax's strong IP portfolio and the potential market for non-mRNA protein vaccines, as acknowledged by the CDC's report on vaccine effectiveness.
Shah Capital Management, Inc. 及其附屬公司已向美國證券交易委員會提交了初步委託書，要求在即將於2024年6月13日舉行的年會上投票反對選舉三名Novavax, Inc.董事會成員。該對沖基金擁有Novavax約7.5％的股份，是其前三名股東之一。該對沖基金還敦促股東投票反對某些公司提案，包括高管薪酬修正案。Shah Capital的行動是在Novavax和賽諾菲最近達成許可協議之後採取的，該協議使Novavax的股票上漲了100％以上。該基金一直對Novavax目前的管理和營銷策略持批評態度，認爲該公司的估值被低估了。Shah Capital已提名兩名新的董事會成員，以幫助扭轉公司的命運。正如疾病預防控制中心關於疫苗有效性的報告所承認的那樣，該基金突顯了Novavax強大的知識產權組合和非mRNA蛋白疫苗的潛在市場。
Shah Capital Management, Inc. 及其附屬公司已向美國證券交易委員會提交了初步委託書，要求在即將於2024年6月13日舉行的年會上投票反對選舉三名Novavax, Inc.董事會成員。該對沖基金擁有Novavax約7.5％的股份，是其前三名股東之一。該對沖基金還敦促股東投票反對某些公司提案，包括高管薪酬修正案。Shah Capital的行動是在Novavax和賽諾菲最近達成許可協議之後採取的，該協議使Novavax的股票上漲了100％以上。該基金一直對Novavax目前的管理和營銷策略持批評態度，認爲該公司的估值被低估了。Shah Capital已提名兩名新的董事會成員，以幫助扭轉公司的命運。正如疾病預防控制中心關於疫苗有效性的報告所承認的那樣，該基金突顯了Novavax強大的知識產權組合和非mRNA蛋白疫苗的潛在市場。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。